LSL Pharma Group Inc.
LSL.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 2.35M | -1.80M | -2.09M | -2.48M | -6.27M |
| Total Depreciation and Amortization | 1.10M | 939.40K | 938.60K | 900.80K | 837.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.75M | 3.71M | 3.68M | 3.40M | 5.77M |
| Change in Net Operating Assets | -2.93M | -4.40M | -5.83M | -5.03M | -5.58M |
| Cash from Operations | -1.24M | -1.55M | -3.29M | -3.21M | -5.24M |
| Capital Expenditure | -1.19M | -2.05M | -1.31M | -802.40K | -486.80K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -2.36M | -1.56M | -1.54M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.87M | -607.70K | -503.90K | -362.90K | -273.10K |
| Cash from Investing | -5.42M | -4.22M | -3.35M | -1.17M | -760.00K |
| Total Debt Issued | 9.69M | 4.24M | 5.42M | 5.82M | 4.96M |
| Total Debt Repaid | -6.46M | -3.74M | -2.94M | -2.13M | -4.55M |
| Issuance of Common Stock | 8.23M | 8.23M | 7.27M | 1.99M | 9.46M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.07M | -696.00K | -973.00K | -565.00K | -1.77M |
| Cash from Financing | 6.87M | 5.91M | 6.47M | 3.79M | 6.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 207.60K | 141.20K | -173.50K | -580.80K | 1.10K |